2. In the Misuse of Drugs Act 1973, in the First Schedule —(a) | in Part 1, in paragraph 16, in item (c), after “alkyl”, insert “, cycloalkyl”; | (b) | in Part 1, in paragraph 16, after item (1), insert — | 1-(1,3-Benzodioxol-5-yl)-2-(cyclohexylamino)propan-1-one (also known as 3,4-methylenedioxy-N-cyclohexylcathinone or 3,4-methylenedioxy-α-cyclohexylaminopropiophenone or N-cyclohexylmethylone or Cyputylone)”; |
|
|
| (c) | in Part 1, in paragraph 16, after item (1A), insert — | 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)pentan-1-one (also known as N,N-dimethylpentylone, dipentylone or bk-DMBDP)”; |
|
|
| (d) | in Part 1, in paragraph 16, after item (17), insert — | 4-Methyl-1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one (also known as α-PiHP or α-pyrrolidinoisohexanophenone)”; |
|
|
| (e) | in Part 1, in paragraph 16, after item (20), insert — | 1-(3-Methylphenyl)-2-(methylamino)propan-1-one (also known as 3-methylmethcathinone, metaphedrone or 3-MMC)”; |
|
|
| (f) | in Part 1, in paragraph 17, in item (c), after “alkyl”, insert “, cycloalkyl”; | (g) | in Part 1, in paragraph 18, in item (1A), before “bromo positional isomers”, insert “N-(1-amino-1-oxohexan-2-yl) isomers and their respective”; | (h) | in Part 1, in paragraph 18, after item (16A), insert — | 2-(2-(4-Butoxybenzyl)-5-nitro-1H-benzo[d]imidazol-1-yl)-N,N-diethylethan-1-amine (also known as butonitazene or butoxynitazene) and its diethylamino and butoxy structural isomers and their respective butoxy positional isomers in the phenyl ring and nitro positional isomers in the 6-membered ring of the benzimidazole structure”; |
|
|
| (i) | in Part 1, in paragraph 18, after item (22), insert — | 5-(Cyclobutylmethyl)-2-(2-phenylpropan-2-yl)-pyrido[4,3-b]indol-1-one (also known as Cumyl-CB-MeGACLONE, Cumyl-CBMGACLONE, cumyl-cyclobutylmethyl-gammacarbolinone or SGT-273) and its phenylpropyl isomers”; |
|
|
| (j) | in Part 1, in paragraph 18, after item (23), insert — | N-Cyclohexyl-2-(1-(4-hydroxypentyl)-1H-indol-3-yl)acetamide and its hydroxy positional isomers in the pentyl group |
| | N-Cyclohexyl-2-(1-pentyl-1H-indol-3-yl)acetamide (also known as CH-PIATA)”; |
|
|
| (k) | in Part 1, in paragraph 18, after item (30A), insert — | N,N-Diethyl-2-(2-(4-propoxybenzyl)-5-nitro-1H-benzo[d]imidazol-1-yl)ethan-1-amine (also known as protonitazene or propoxynitazene) and its diethylamino structural isomers and their respective propoxy positional isomers in the phenyl ring and nitro positional isomers in the 6-membered ring of the benzimidazole structure”; |
|
|
| (l) | in Part 1, in paragraph 18, after item (43), insert — | 2-(2-(4-Ethoxybenzyl)-1H-benzo[d]imidazol-1-yl)-N,N-diethylethan-1-amine (also known as etodesnitazene, etazene, etazen, etazone or desnitroetonitazene) and its diethylamino structural isomers and their respective ethoxy positional isomers in the phenyl ring |
| | 2-(4-Ethoxybenzyl)-5-nitro-1-(2-pyrrolidin-1-ylethyl)-1H-benzimidazole (also known as etonitazepyne or N-pyrrolidino etonitazene) and its ethoxy positional isomers in the phenyl ring and their respective nitro positional isomers in the 6-membered ring of the benzimidazole structure”; |
|
|
| (m) | in Part 1, in paragraph 18, after item (51A), insert — | N’-(1-Hexyl-2-oxoindolin-3-ylidene)-4-hydroxybenzohydrazide and its hydroxy positional isomers in the phenyl ring”; |
|
|
| (n) | in Part 1, in paragraph 18, after item (54), insert — | N’-(1-(4-Hydroxycyclohexylmethyl)-2-oxoindolin-3-ylidene)benzohydrazide and its hydroxy positional isomers in the cyclohexyl group”; |
|
|
| (o) | in Part 1, in paragraph 18, after item (70), insert — | 1-(2-Methyl-4-(3-phenyl-prop-2-en-1-yl)-piperazin-1-yl)-1-butanone (also known as 2-methyl-AP-237 or 2-methyl buccinazine) and its methyl positional isomers in the piperazinyl ring”; |
|
|
| (p) | in Part 4, in the definition of “cannabinol derivatives”, after “or its tetrahydro derivatives”, insert “and any compound structurally derived from such derivatives by substitution of any of the hydrogen atoms”; | (q) | in Part 4, in the definition of “type A substituent”, replace paragraph (k) with —“(k) | an arylalkyl group; or”; and |
|
| (r) | in Part 4, in the definition of “type B substituent”, replace paragraph (f) with —“(f) | an arylalkyl group;”. |
|
|
|